2028 Immune Response Licensing 
Codon
SEPTEMBER 29, 2024
2028 Over the next year, the scientific community ferociously interrogated the model. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. Prior therapeutic viruses had had their replication capabilities crippled out of fear of severe immune responses.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.
Expert insights. Personalized for you.
132 
Let's personalize your content